Should You Invest in Applied Therapeutics Inc (APLT) Now?
The 36-month beta value for APLT is at 1.89. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APLT is 89.33M, and currently, shorts hold a 5.57% of that float. The average trading volume for APLT on April 19, 2024 was 1.84M shares.
3 Tiny Stocks Primed to Explode
The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
APLT) stock’s latest price update
Applied Therapeutics Inc (NASDAQ: APLT)’s stock price has decreased by -1.86 compared to its previous closing price of 4.83. However, the company has seen a -11.24% decrease in its stock price over the last five trading sessions. Reuters reported 2024-03-28 that The U.S. Food and Drug Administration has extended its review of Applied Therapeutics’ experimental drug to treat galactosemia, a rare genetic metabolic disease, the company said on Thursday.
APLT’s Market Performance
APLT’s stock has fallen by -11.24% in the past week, with a monthly drop of -24.28% and a quarterly rise of 90.36%. The volatility ratio for the week is 7.65% while the volatility levels for the last 30 days are 7.19% for Applied Therapeutics Inc The simple moving average for the last 20 days is -21.28% for APLT stock, with a simple moving average of 56.09% for the last 200 days.
Analysts’ Opinion of APLT
Many brokerage firms have already submitted their reports for APLT stocks, with RBC Capital Mkts repeating the rating for APLT by listing it as a “Outperform.” The predicted price for APLT in the upcoming period, according to RBC Capital Mkts is $12 based on the research report published on March 26, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see APLT reach a price target of $12. The rating they have provided for APLT stocks is “Outperform” according to the report published on February 22nd, 2024.
Barclays gave a rating of “Equal Weight” to APLT, setting the target price at $7 in the report published on January 04th of the previous year.
APLT Trading at -15.07% from the 50-Day Moving Average
After a stumble in the market that brought APLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.52% of loss for the given period.
Volatility was left at 7.19%, however, over the last 30 days, the volatility rate increased by 7.65%, as shares sank -31.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +50.96% upper at present.
During the last 5 trading sessions, APLT fell by -11.24%, which changed the moving average for the period of 200-days by +270.31% in comparison to the 20-day moving average, which settled at $5.91. In addition, Applied Therapeutics Inc saw 41.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLT starting from Shendelman Shoshana, who sale 318,573 shares at the price of $5.39 back on Mar 14 ’24. After this action, Shendelman Shoshana now owns 3,817,814 shares of Applied Therapeutics Inc, valued at $1,717,108 using the latest closing price.
Perfetti Riccardo, the Chief Medical Officer of Applied Therapeutics Inc, sale 110,804 shares at $5.39 during a trade that took place back on Mar 14 ’24, which means that Perfetti Riccardo is holding 1,031,537 shares at $597,234 based on the most recent closing price.
Stock Fundamentals for APLT
Current profitability levels for the company are sitting at:
- -6.46 for the present operating margin
- 0.93 for the gross margin
The net margin for Applied Therapeutics Inc stands at -11.91. The total capital return value is set at 3.95. Equity return is now at value -682.16, with -189.48 for asset returns.
Based on Applied Therapeutics Inc (APLT), the company’s capital structure generated -0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -71.01.
Currently, EBITDA for the company is -64.18 million with net debt to EBITDA at 1.4. When we switch over and look at the enterprise to sales, we see a ratio of 49.27. The receivables turnover for the company is 35.06for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.80.
Conclusion
In conclusion, Applied Therapeutics Inc (APLT) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.